Astellas Pharma Balance Sheet Health
Financial Health criteria checks 4/6
Astellas Pharma has a total shareholder equity of ¥1,529.8B and total debt of ¥935.8B, which brings its debt-to-equity ratio to 61.2%. Its total assets and total liabilities are ¥3,462.2B and ¥1,932.4B respectively. Astellas Pharma's EBIT is ¥170.0B making its interest coverage ratio 38.6. It has cash and short-term investments of ¥293.0B.
Key information
61.2%
Debt to equity ratio
JP¥935.83b
Debt
| Interest coverage ratio | 38.6x |
| Cash | JP¥292.99b |
| Equity | JP¥1.53t |
| Total liabilities | JP¥1.93t |
| Total assets | JP¥3.46t |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: ALPM.Y's short term assets (¥1,203.0B) exceed its short term liabilities (¥1,093.4B).
Long Term Liabilities: ALPM.Y's short term assets (¥1,203.0B) exceed its long term liabilities (¥839.0B).
Debt to Equity History and Analysis
Debt Level: ALPM.Y's net debt to equity ratio (42%) is considered high.
Reducing Debt: ALPM.Y's debt to equity ratio has increased from 0.2% to 61.2% over the past 5 years.
Debt Coverage: ALPM.Y's debt is well covered by operating cash flow (21.5%).
Interest Coverage: ALPM.Y's interest payments on its debt are well covered by EBIT (38.6x coverage).